Guardant Health Revenue Jumps 38% on Shield Test Momentum, Losses Narrow

TL;DR

**GH is burning cash but Shield's FDA approval and revenue surge make it a speculative buy for long-term growth in liquid biopsy.**

AI Summary

Guardant Health, Inc. (GH) reported a significant increase in revenue for the three months ended September 30, 2025, reaching $265.2 million, up from $191.5 million in the prior year, representing a 38.5% increase. For the nine months ended September 30, 2025, revenue grew to $700.8 million from $537.2 million, a 30.4% increase. Despite this revenue growth, the company continued to incur net losses, with a net loss of $92.7 million for the quarter, an improvement from $107.8 million in the same period last year. The nine-month net loss was $287.8 million, down from $325.4 million. Operating expenses increased across the board, with sales and marketing expense rising to $127.4 million for the quarter from $97.9 million, and research and development expense increasing to $89.9 million from $87.3 million. A key business change was the FDA approval of the Shield blood test for colorectal cancer screening in July 2024, and its commercial availability in August 2024, which also secured Medicare coverage. The company's total liabilities increased to $1.63 billion from $1.62 billion, while total stockholders' deficit widened significantly to $354.5 million from $139.6 million at December 31, 2024, partly due to a $45.0 million repurchase of treasury stock. Cash and cash equivalents increased to $580.0 million from $525.5 million.

Why It Matters

Guardant Health's strong revenue growth, driven by the FDA-approved Shield blood test, signals significant market penetration in the colorectal cancer screening space, potentially disrupting traditional screening methods. This is crucial for investors as it validates the company's long-term strategy and product pipeline, offering a competitive edge against other diagnostic firms. For patients, the Shield test provides a less invasive screening option, potentially increasing compliance and early detection rates. Employees benefit from the company's expanding market presence and product success. The broader market could see a shift in diagnostic testing paradigms, with Guardant Health positioned as a leader in liquid biopsy, influencing healthcare providers and insurance coverage decisions.

Risk Assessment

Risk Level: medium — Guardant Health reported a net loss of $92.7 million for the quarter and a total stockholders' deficit of $354.5 million as of September 30, 2025, indicating ongoing unprofitability and negative equity. While net cash used in operating activities improved to $158.4 million for the nine months ended September 30, 2025, from $175.3 million in the prior year, the company continues to consume significant cash from operations. The substantial increase in sales and marketing expenses to $127.4 million for the quarter also highlights the high cost of market penetration.

Analyst Insight

Investors should closely monitor Guardant Health's ability to convert its impressive revenue growth from the Shield test into profitability and positive cash flow. While the FDA approval and Medicare coverage are strong catalysts, the widening stockholders' deficit and continued net losses warrant caution. Consider this a growth stock with significant potential but also notable execution risks; a 'wait and see' approach on sustained profitability might be prudent before a large investment.

Financial Highlights

debt To Equity

Not Applicable (Stockholders' Deficit)

revenue

$265.2M

operating Margin

Not Disclosed

total Assets

$1.28B

total Debt

$1.11B

net Income

-$92.7M

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

$580.0M

revenue Growth

+38.5%

Revenue Breakdown

Key Numbers

• $265.2M — Revenue for Q3 2025 (Increased 38.5% from $191.5M in Q3 2024)
• $700.8M — Revenue for nine months ended Sept 30, 2025 (Increased 30.4% from $537.2M in the prior year period)
• $92.7M — Net loss for Q3 2025 (Improved from $107.8M net loss in Q3 2024)
• $287.8M — Net loss for nine months ended Sept 30, 2025 (Improved from $325.4M net loss in the prior year period)
• $127.4M — Sales and marketing expense for Q3 2025 (Increased from $97.9M in Q3 2024)
• $89.9M — Research and development expense for Q3 2025 (Increased from $87.3M in Q3 2024)
• $354.5M — Total Stockholders' Deficit as of Sept 30, 2025 (Widened from $139.6M as of Dec 31, 2024)
• $45.0M — Repurchase of treasury stock (Contributed to the increase in stockholders' deficit)
• $580.0M — Cash and cash equivalents as of Sept 30, 2025 (Increased from $525.5M as of Dec 31, 2024)
• $158.4M — Net cash used in operating activities for nine months ended Sept 30, 2025 (Improved from $175.3M in the prior year period)

Key Players & Entities

• Guardant Health, Inc. (company) — registrant of the 10-Q filing
• Shield blood test (product) — FDA-approved test for colorectal cancer screening
• FDA (regulator) — approved the Shield blood test
• Medicare (regulator) — provides coverage for the Shield blood test
• National Comprehensive Cancer Network (company) — included Shield blood test in updated colorectal cancer screening guidelines
• TwinStrand Biosciences, Inc. (company) — party in intellectual property dispute
• University of Washington (company) — party in intellectual property dispute
• Guardant360 Liquid test (product) — comprehensive liquid biopsy test
• Guardant Reveal blood test (product) — detects residual and recurring disease
• GuardantINFORM platform (product) — in-silico research platform for biopharmaceutical companies

FAQ

Risk Factors

• FDA Approval and Reimbursement Uncertainty [high — regulatory]: While the Shield test received FDA approval and Medicare coverage, ongoing regulatory scrutiny and the need for continued positive coverage decisions from payers remain critical. Delays or adverse changes in reimbursement could significantly impact revenue and adoption.
• Sustained Net Losses and Cash Burn [high — financial]: The company continues to incur substantial net losses, with a $92.7 million loss in Q3 2025, despite significant revenue growth. The accumulated deficit has widened to $2.87 billion. While cash and cash equivalents increased to $580.0 million, the ongoing operational losses necessitate careful cash management and potential future financing.
• Scaling Sales and Marketing Efforts [medium — operational]: Sales and marketing expenses increased by 30.1% to $127.4 million in Q3 2025, reflecting investments in commercializing new tests like Shield. The ability to efficiently scale these efforts and achieve profitable customer acquisition is crucial for future growth.
• Increasing Debt Load [medium — financial]: Total liabilities stand at $1.63 billion, with convertible senior notes representing a significant portion. While the company has cash reserves, the substantial debt obligations and interest payments add financial pressure.
• Research and Development Investment [medium — operational]: R&D expenses increased to $89.9 million in Q3 2025. Continued investment is necessary for innovation, but the company must balance this with the need to achieve profitability.
• Widening Stockholders' Deficit [medium — financial]: The total stockholders' deficit has widened significantly to $354.5 million, partly due to a $45.0 million treasury stock repurchase. This indicates that the company's liabilities exceed its assets.
• Competition in the Liquid Biopsy Market [medium — market]: The liquid biopsy market is competitive, with established players and emerging companies. Guardant Health must continue to differentiate its offerings and demonstrate clinical utility and cost-effectiveness to maintain market share.

Industry Context

The liquid biopsy market is rapidly evolving, driven by advancements in genomic sequencing and the demand for less invasive diagnostic tools. Guardant Health operates in a competitive landscape with significant players focusing on early cancer detection and treatment selection. Key trends include the expansion of screening tests for asymptomatic individuals and the integration of multi-cancer early detection (MCED) technologies.

Regulatory Implications

Guardant Health's reliance on FDA approvals and favorable reimbursement decisions from Medicare and private payers presents significant regulatory risk. The Shield test's recent FDA approval and Medicare coverage are positive developments, but ongoing compliance and potential changes in regulatory pathways for diagnostic tests are critical considerations.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-07-01: FDA Approval of Shield Blood Test — Major regulatory milestone for colorectal cancer screening, opening up a significant new market opportunity.
• 2025-08-01: Commercial Availability of Shield Test — Enabled revenue generation from the newly approved test and secured Medicare coverage.
• 2025-09-30: End of Q3 2025 — Reporting period for the financial results showing strong revenue growth but continued net losses.
• 2024-12-31: End of Fiscal Year 2024 — Prior period balance sheet data for comparison, showing a smaller stockholders' deficit.

Glossary

Stockholders' Deficit

A situation where a company's total liabilities exceed its total assets, resulting in a negative equity position. (Indicates Guardant Health's current financial structure where liabilities outweigh assets, impacting its balance sheet health.)

Treasury Stock

Shares of a company's own stock that it has repurchased from the open market. (The $45.0 million repurchase of treasury stock directly contributed to the widening of the stockholders' deficit.)

Convertible Senior Notes

Debt securities that can be converted into a predetermined amount of the issuer's equity. (A significant component of Guardant Health's liabilities, representing a substantial financial obligation.)

Deferred Revenue

Revenue that has been received by a company but not yet earned, as the goods or services have not been delivered or rendered. (An increase in deferred revenue suggests future revenue potential as services are rendered.)

Right-of-use Assets

An intangible asset representing the right to use an underlying asset for a specified period, typically under a lease agreement. (Represents the company's long-term lease obligations, such as for office or lab space.)

Year-Over-Year Comparison

Compared to the prior year period, Guardant Health has demonstrated robust revenue growth, with a 38.5% increase in Q3 2025 revenue to $265.2 million. This growth is accompanied by a significant increase in operating expenses, particularly in sales and marketing, which rose by 30.1%. While net losses have narrowed slightly, the company's financial position shows a widening stockholders' deficit to $354.5 million from $139.6 million at the end of the previous fiscal year, indicating increased liabilities relative to assets. New risks related to scaling commercial operations and continued regulatory navigation are now more prominent.

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 par value per share GH The Nasdaq Glo

Filing Documents

• gh-20250930.htm (10-Q) — 1550KB
• gh-9302025x10qxex311.htm (EX-31.1) — 10KB
• gh-9302025x10qxex312.htm (EX-31.2) — 10KB
• gh-9302025x10qxex313.htm (EX-31.3) — 10KB
• gh-9302025x10qxex321.htm (EX-32.1) — 6KB
• gh-9302025x10qxex322.htm (EX-32.2) — 6KB
• gh-9302025x10qxex323.htm (EX-32.3) — 6KB
• 0001576280-25-000277.txt ( ) — 8969KB
• gh-20250930.xsd (EX-101.SCH) — 52KB
• gh-20250930_cal.xml (EX-101.CAL) — 87KB
• gh-20250930_def.xml (EX-101.DEF) — 312KB
• gh-20250930_lab.xml (EX-101.LAB) — 727KB
• gh-20250930_pre.xml (EX-101.PRE) — 520KB
• gh-20250930_htm.xml (XML) — 1490KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Page Item 1. Unaudited Condensed Consolidated Financial Statements 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Condensed Consolidated Statements of Stockholders' Equity (Deficit) 6 Condensed Consolidated Statements of Cash Flows 8 Notes to the Unaudited Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 49 Item 4.

Controls and Procedures

Controls and Procedures 49

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 51 Item 1A.

Risk Factors

Risk Factors 51 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 51 Item 3. Defaults Upon Senior Securities 51 Item 4. Mine Safety Disclosures 51 Item 5. Other Information 51 Item 6. Exhibits 52

Signatures

Signatures 53

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, including the section titled " Management ' s Discussion and Analysis of Financial Condition and Results of Operations ," contains forward-looking statements regarding future events and our future results that are based on our current expectations, estimates, forecasts and projections as well as the current beliefs and assumptions of our management, including about our business, our financial condition, our results of operations, our cash flows, and the industry and environment in which we operate. Statements that include words such as "believe," "may," "will," "estimate," "continue," "anticipate," "would," "could," "should," "intend" and "expect," variations of these words, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A," Risk Factors " and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2024, in Part II, Item 1A, " Risk Factors " and elsewhere in this Quarterly Report on Form 10-Q, and in other reports we file with the U.S. Securities and Exchange Commission, or the SEC. While forward-looking statements are based on the reasonable expectations of our management at the time that they are made, you should not rely on them. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, whether as a result of new information, future events or otherwise, except as may be required by law. Each of the terms the "Company," "we," "our," "us" and similar terms used herein refer collectively t

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Unaudited Condensed Consolidated Financial Statements

Item 1. Unaudited Condensed Consolidated Financial Statements Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 580,013 $ 525,540 Short-term marketable debt securities — 314,438 Accounts receivable, net 115,585 110,253 Inventory, net 90,489 71,083 Prepaid expenses and other current assets, net 42,798 33,800 Total current assets 828,885 1,055,114 Restricted cash 109,502 104,215 Property and equipment, net 124,609 136,813 Right-of-use assets, net 163,550 142,265 Intangible assets, net 5,477 6,760 Goodwill 3,290 3,290 Other assets, net 41,473 37,152 Total Assets $ 1,276,786 $ 1,485,609 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable $ 20,142 $ 38,551 Accrued compensation 98,209 83,219 Accrued expenses 71,707 68,345 Deferred revenue 46,861 35,468 Total current liabilities 236,919 225,583 Convertible senior notes, net, principal amount of $ 1,090,660 and $ 1,150,000 as of September 30, 2025 and December 31, 2024, respectively 1,114,594 1,142,547 Long-term operating lease liabilities 185,387 164,292 Other long-term liabilities 94,359 92,834 Total Liabilities 1,631,259 1,625,256 Commitments and contingencies (Note 8) Stockholders' deficit: Preferred stock, par value of $ 0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2025 and December 31, 2024 — — Common stock, par value of $ 0.00001 per share; 350,000,000 shares authorized; 125,982,066 and 123,994,006 shares issued as of September 30, 2025 and December 31, 2024; and 125,005,715 and 123,994,006 shares outstanding as of September 30, 2025 and December 31, 2024, respectively 1 1 Treasury stock, at cost, 976,351 shares as of September 30, 2025 ( 45,010 ) — Additional paid-in capital 2,560,814 2,443,788 Accumulated ot